| Literature DB >> 27989322 |
Timothy H J Goodship1, H Terence Cook2, Fadi Fakhouri3, Fernando C Fervenza4, Véronique Frémeaux-Bacchi5, David Kavanagh6, Carla M Nester7, Marina Noris8, Matthew C Pickering2, Santiago Rodríguez de Córdoba9, Lubka T Roumenina10, Sanjeev Sethi11, Richard J H Smith12.
Abstract
In both atypical hemolytic uremic syndrome (aHUS) and C3 glomerulopathy (C3G) complement plays a primary role in disease pathogenesis. Herein we report the outcome of a 2015 Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference where key issues in the management of these 2 diseases were considered by a global panel of experts. Areas addressed included renal pathology, clinical phenotype and assessment, genetic drivers of disease, acquired drivers of disease, and treatment strategies. In order to help guide clinicians who are caring for such patients, recommendations for best treatment strategies were discussed at length, providing the evidence base underpinning current treatment options. Knowledge gaps were identified and a prioritized research agenda was proposed to resolve outstanding controversial issues.Entities:
Keywords: C3 glomerulopathy; anti-complement therapies; atypical hemolytic uremic syndrome; complement; glomerulonephritis; kidney disease
Mesh:
Substances:
Year: 2016 PMID: 27989322 DOI: 10.1016/j.kint.2016.10.005
Source DB: PubMed Journal: Kidney Int ISSN: 0085-2538 Impact factor: 10.612